PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Announces Presentations at the 252nd American Chemical Society National Meeting & Exposition
WEST LAFAYETTE, Ind. , Aug. 15, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that five posters will be presented by Endocyte scientists at the 252
View HTML
Toggle Summary Endocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference
WEST LAFAYETTE, Ind. , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2016 Wedbush
View HTML
Toggle Summary Endocyte Reports Second Quarter 2016 Financial Results
- Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456 - - Initiating EC1456 Expansion Cohort in Targeted Population of Folate Receptor-Positive Non-Small Cell Lung Cancer Patients - - Data Presentations Expected for EC1456 and EC1169 in the Second Half of 2016 - -  
View HTML
Toggle Summary Endocyte Announces Second Quarter 2016 Earnings Conference Call
WEST LAFAYETTE, Ind. , July 28, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Thursday, August 4th , at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Appoints Mike Sherman as President and Chief Executive Officer
WEST LAFAYETTE, Ind. , June 20, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike Sherman has been appointed president and chief executive
View HTML
Toggle Summary Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
WEST LAFAYETTE, Ind. , May 26, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets,
View HTML
Toggle Summary Endocyte Reports First Quarter 2016 Financial Results
- Data from Phase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented at ASCO - - Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016 - - Promising Preclinical Data Demonstrates Unique SMDC Applications in Immuno-Oncology -       -  Conference Call
View HTML
Toggle Summary Endocyte Announces First Quarter 2016 Earnings Conference Call
WEST LAFAYETTE, Ind. , April 27, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th , at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016
Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies   Potentially meaningful application of SMDC platform in immuno-oncology WEST LAFAYETTE, Ind. , April 19, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc.
View HTML
Toggle Summary Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016
WEST LAFAYETTE, Ind. , April 11, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the
View HTML